Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a (GT1a) and GT1b HCV-infected subjects, median viral load reductions ranged from 2.3 to 3.3 log(10) HCV RNA IU/ml across dosing cohorts (1, 3, 10, 30, or 90 mg once daily). Here, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wong, Kelly A., Worth, Angela, Martin, Ross, Svarovskaia, Evguenia, Brainard, Diana M., Lawitz, Eric, Miller, Michael D., Mo, Hongmei
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2013
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3837913/
https://ncbi.nlm.nih.gov/pubmed/23877691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02193-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados